Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17665424rdf:typepubmed:Citationlld:pubmed
pubmed-article:17665424lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17665424lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17665424lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:17665424lifeskim:mentionsumls-concept:C0024501lld:lifeskim
pubmed-article:17665424lifeskim:mentionsumls-concept:C0003872lld:lifeskim
pubmed-article:17665424lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:17665424lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:17665424lifeskim:mentionsumls-concept:C0449258lld:lifeskim
pubmed-article:17665424lifeskim:mentionsumls-concept:C0666743lld:lifeskim
pubmed-article:17665424lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:17665424lifeskim:mentionsumls-concept:C0439234lld:lifeskim
pubmed-article:17665424lifeskim:mentionsumls-concept:C1883709lld:lifeskim
pubmed-article:17665424pubmed:issue8lld:pubmed
pubmed-article:17665424pubmed:dateCreated2007-8-28lld:pubmed
pubmed-article:17665424pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17665424pubmed:abstractTextTo evaluate the effect of infliximab on progression of structural damage over 1 year in patients with active psoriatic arthritis (PsA) enrolled in the Induction and Maintenance Psoriatic Arthritis Clinical Trial 2.lld:pubmed
pubmed-article:17665424pubmed:languageenglld:pubmed
pubmed-article:17665424pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17665424pubmed:citationSubsetAIMlld:pubmed
pubmed-article:17665424pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17665424pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17665424pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17665424pubmed:statusMEDLINElld:pubmed
pubmed-article:17665424pubmed:monthAuglld:pubmed
pubmed-article:17665424pubmed:issn0004-3591lld:pubmed
pubmed-article:17665424pubmed:authorpubmed-author:GladmanD DDDlld:pubmed
pubmed-article:17665424pubmed:authorpubmed-author:KruegerG GGGlld:pubmed
pubmed-article:17665424pubmed:authorpubmed-author:GeusensPPlld:pubmed
pubmed-article:17665424pubmed:authorpubmed-author:HalterDDlld:pubmed
pubmed-article:17665424pubmed:authorpubmed-author:ZhouBBlld:pubmed
pubmed-article:17665424pubmed:authorpubmed-author:BeutlerAAlld:pubmed
pubmed-article:17665424pubmed:authorpubmed-author:GuzzoCClld:pubmed
pubmed-article:17665424pubmed:authorpubmed-author:van der...lld:pubmed
pubmed-article:17665424pubmed:authorpubmed-author:de VlamKKlld:pubmed
pubmed-article:17665424pubmed:authorpubmed-author:AntoniCClld:pubmed
pubmed-article:17665424pubmed:authorpubmed-author:KavanaughAAlld:pubmed
pubmed-article:17665424pubmed:authorpubmed-author:BirbaraCClld:pubmed
pubmed-article:17665424pubmed:authorpubmed-author:DooleyL TLTlld:pubmed
pubmed-article:17665424pubmed:issnTypePrintlld:pubmed
pubmed-article:17665424pubmed:volume56lld:pubmed
pubmed-article:17665424pubmed:ownerNLMlld:pubmed
pubmed-article:17665424pubmed:authorsCompleteYlld:pubmed
pubmed-article:17665424pubmed:pagination2698-707lld:pubmed
pubmed-article:17665424pubmed:meshHeadingpubmed-meshheading:17665424...lld:pubmed
pubmed-article:17665424pubmed:meshHeadingpubmed-meshheading:17665424...lld:pubmed
pubmed-article:17665424pubmed:meshHeadingpubmed-meshheading:17665424...lld:pubmed
pubmed-article:17665424pubmed:meshHeadingpubmed-meshheading:17665424...lld:pubmed
pubmed-article:17665424pubmed:meshHeadingpubmed-meshheading:17665424...lld:pubmed
pubmed-article:17665424pubmed:meshHeadingpubmed-meshheading:17665424...lld:pubmed
pubmed-article:17665424pubmed:meshHeadingpubmed-meshheading:17665424...lld:pubmed
pubmed-article:17665424pubmed:meshHeadingpubmed-meshheading:17665424...lld:pubmed
pubmed-article:17665424pubmed:meshHeadingpubmed-meshheading:17665424...lld:pubmed
pubmed-article:17665424pubmed:meshHeadingpubmed-meshheading:17665424...lld:pubmed
pubmed-article:17665424pubmed:meshHeadingpubmed-meshheading:17665424...lld:pubmed
pubmed-article:17665424pubmed:meshHeadingpubmed-meshheading:17665424...lld:pubmed
pubmed-article:17665424pubmed:meshHeadingpubmed-meshheading:17665424...lld:pubmed
pubmed-article:17665424pubmed:year2007lld:pubmed
pubmed-article:17665424pubmed:articleTitleInfliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.lld:pubmed
pubmed-article:17665424pubmed:affiliationLeiden University Medical Center, Leiden, The Netherlands. d.vanderheijde@kpnplanet.nllld:pubmed
pubmed-article:17665424pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17665424pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:17665424pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:17665424pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:17665424pubmed:publicationTypeClinical Trial, Phase IIIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17665424lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17665424lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17665424lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17665424lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17665424lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17665424lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17665424lld:pubmed